President's Message

History of Challenges

Taiho Pharmaceutical Co., Ltd., was established as a member of the Otsuka Group in 1963. Ever since, the whole company has worked as a united team to provide quality products that patients and consumers around the world can use with confidence and to disseminate appropriate safety information.

Looking back over the history of the companyʼs pharmaceutical business since its establishment, we recall the launch of the oral tegafur formulation Futraful in Japan in 1974, one of the worldʼs first oral anticancer agents. Carrying on with research and development to resolve the challenge of improving safety while increasing efficacy, we demonstrated the effectiveness of UFT, a formulation of tegafur and uracil, in adjuvant chemotherapy for gastric cancer, breast cancer, colon cancer, and lung cancer. UFT was launched in Japan in 1984. TS-1 (a formulation of tegafur, gimeracil, and oteracil potassium), launched in Japan in 1999, established the standard for treatment of advanced or recurrent gastric cancer and for adjuvant chemotherapy for gastric and pancreatic cancers in Japan.

Further, in 2014 we launched the oral anticancer drug LONSURF (trifluridine and tipiracil hydrochloride), which has a new mechanism of action. In 2015, LONSURF became the first Taiho product to be marketed directly by the company in the U.S. In 2016, the drug obtained approval in Europe through our French partner, Servier, and it is being progressively launched in countries there.

Each of these examples shows how Taiho Pharmaceutical has continued to embrace the challenge of developing drugs that can contribute to cancer chemotherapy around the world. Meanwhile, we have also worked intensively on the development of original, innovative pharmaceuticals in the immunology, allergy, and urology fields. We are continuing to do everything we can to create new drugs that help to improve quality of life for patients and contribute to full recovery.

The company has also developed much-loved brands in the consumer healthcare market, like Tiovita, Solmack and Harncare. We are determined to continue to take on the challenge of creating and nurturing unique brands that consumers love for many years.

Spirit of Globalization

Taiho Pharmaceutical is conducting numerous global clinical trials via its existing clinical development centers in Japan, the U.S., the U.K., China and Singapore. At Taiho, we are pursuing simultaneous global development of a number of promising compounds coming out of our Discovery and Preclinical Research Division, seeking to get these new drugs ready for patients around the world as soon as possible.

Of course, development is only the first step in getting products to patients. We have made the strategic decision to market key products globally. We are now reinforcing our marketing structure to accomplish this in the U.S. and in Asian countries, as well as other markets including Europe. We believe this aggressive approach will significantly expand the companyʼs presence not only in Japan, but also worldwide. As part of this, in December 2016, we established a new subsidiary in Canada. The most important thing for our business development will be securing, training, and properly deploying people with great talent. Our unwavering commitment is to continue developing world-class human resources and bringing in top talent of diverse backgrounds.

Commitment to Compliance

In line with Taiho Pharmaceuticalʼs corporate philosophy—“We strive to improve human health and contribute to a society enriched by smiles”—each and every employee strives to ensure compliance. Our people take the companyʼs close involvement with human life seriously and understand the importance of complying with the letter and spirit of the law and codes of conduct. Going forward, our entire team will work as one to ensure that Taiho Pharmaceutical remains a valuable contributor to the health of people worldwide by developing and supplying outstanding pharmaceuticals.

Masayuki Kobayashi
President and Representative Director